Webinar: Breast Cancer 2023 Data & Post-SABCS Summary

ctDNA in drug development for breast cancer Multiple studies have demonstrated that detection of molecular residual disease (MRD) is associated with poor prognosis in breast cancer. Ongoing prospective clinical trials are underway to assess the efficacy of therapeutic interception. Our expert speakers will discuss the latest data from SABCS 2023 and recent publications and congresses. This will be followed by a panel discussion on the future directions and implications for drug development and clinical trial design in this rapidly evolving space. Findings presented will span treatment settings.